Dr. Parida advises on key high value, big impact assignments in VC/PE investment, entrepreneurship, startups, M&A and economic policy matters.
He advises on a wide range of topics: technology, social media, mobile, e-commerce, sharing economy, 3D-printing, robotics, artificial intelligence, sensors, biotech, life sciences, healthcare, drug development, medical devices, alternative energy, clean technology, and space exploration technology.
Dr. Parida is often asked to speak on topics of VC/PE investment, entrepreneurship, startup, and innovation. He has participated in numerous conferences and business plan competition around the globe.
Dr. Parida has advised countries, international trade organizations, cities, and universities on developing policies, sourcing the best of worldwide expertise, and executing plans on empowering entrepreneurs, creating startup ecosystem, setting up incubators, accelerators and investment (angel/VC) funds.
Dr. Parida has advised VC/angel/HNW individuals on deal sourcing, new market and industry expansion, identifying investment opportunity, investment evaluation, valuation and term sheets.
Dr. Parida has offered lectures on a variety of topics in entrepreneurship, startups, and innovation to political leaders, government decision makers, thought leaders, business houses, and at Universities. He has also offered tailor-made “Ideas to IPO: The Startup Master Class” across the globe.
Dr. Parida has evaluated more than 2,000 business plans and presented many companies to investors that has led, in total, to more than $300M in funding. He has advised start-up companies in all aspects of business – business plan development, product-market fit, client acquisition, strategic partnership development, fund raising, valuation, term-sheet, recruitment of senior management, and board of advisors.
Dr. Parida has advised companies on M&A including reverse mergers by taking private companies public.
He has advised international government agencies, businesses and investment houses to attract and access US private equity funds.